LQDA · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$57.40-1.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
Just reported
From Liquidia Corporation's results release of November 10, 2026; its quarterly report has since been filed.
Actual
$225.3M
+315% y/y
+31% q/q
Guided
—
No guide given
Actual
-$2.64
Guided
—
No guide given
Actual
-$263.5M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $225.3M | $54.3M | +314.60% |
| Profit | -$236.3M | -$3.5M | -6,589.16% |
| Profit per share | -$2.64 | -$0.04 | -6,500.00% |
| Free Cash Flow | $129.8M | -$10.7M | +1,315.02% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Liquidia Corporation reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
(liposomal treprostinil inhalation suspension) L606 is an investigational, extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. The L606 suspension uses a proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time. L606 is currently being evaluated in an open-label study in the United States for treatment of PAH and PH-ILD and is being evaluated in Re-Spire, a global pivotal placebo-controlled efficacy study to evaluate L606 in adults for the treatment of PH-ILD.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Liquidia Corporation’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.